Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

The DEAD-box helicase family member DDX3X (DBX, DDX3) functions in nearly all stages
of RNA metabolism and participates in the progression of many diseases, including virus …

Abstract KRAS G12C mutation is prevalent in~ 4% of colorectal cancer (CRC) and is
associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest …

In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode
four highly homologous proteins. RAS proteins are small GTPases involved in a broad …

Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer associated with
advanced age and immunosuppression. Over the past decade, an association has been …

Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

ERK1 and ERK2 are key protein kinases that contribute to the Ras-Raf-MEK-ERK MAP
kinase signalling module. This pathway participates in the control of numerous processes …

JAK/STAT signaling pathway is one of the important regulatory signaling cascades for the
myriad of cellular processes initiated by various types of ligands such as growth factors …

Lung cancer remains the leading cause of cancer-related death. In addition to chest X-rays
and computerised tomography, the detection of cancer biomarkers serves as an emerging …

The extracellular signal-regulated kinases 1/2 (ERK) are central signaling components that
regulate stimulated cellular processes such as proliferation and differentiation. When …